ASTEPRO 0.15% Rx
Generic Name and Formulations:
Azelastine HCl 0.15% (205.5mcg/spray;) aqueous nasal spray; contains benzalkonium chloride.
Indications for ASTEPRO 0.15%:
Seasonal and perennial allergic rhinitis.
Seasonal: 1 or 2 sprays in each nostril twice daily or 2 sprays in each nostril once daily. Perennial: 2 sprays in each nostril twice daily.
Avoid eyes, mouth. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Caution with other antihistamines.
Bitter taste, nasal discomfort, epistaxis, headache, fatigue, somnolence, sneezing.
Spray—17mL (106 sprays), 30mL (200 sprays)
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally